Audeotherapy.com
Audeotherapy.com

HIPAA Policy

HIPAA Policy

Notice of Privacy Practices
This notice explains how your medical information may be used and shared, and how you can access it. Please review it carefully.

Summary of Your Privacy Rights

Your health information may be used or shared for the following purposes:

Providing Care: To coordinate and manage your healthcare, including referrals and consultations between healthcare providers.
Processing Payments: To interact with health plans, insurance providers, or workers’ compensation programs for billing and payments.
Informing You: To notify you about available health benefits, services, or prescription readiness.
Legal Requirements: To report cases of abuse, neglect, or domestic violence to appropriate authorities as required by law.
Family and Caregiver Communication: To share relevant information with designated individuals, such as family members or caregivers.

Other uses of your health information include:

  • Business Associates: To ensure secure record-keeping with contracted entities.
  • Healthcare Operations: To enhance quality of care and ensure public safety.
  • Health Oversight Activities: To comply with federal or state regulatory requirements.
  • Legal and Security Reasons: For lawful purposes such as subpoenas, military, or national security.
  • Organ and Tissue Donation: To support organ or tissue donation programs.
  • Data Breach Notifications: To notify you in case of a breach involving your health information.
  • Law Enforcement: To comply with legal requirements or investigations.
  • Coroner, Medical Examiner, or Funeral Director: For investigations or related duties.
  • FDA Reporting: To report adverse events as legally required.
  • Controlled Substance Reporting: To meet legal obligations for reporting to the Department of Justice.

Your Rights

You have the right to:

  • View and obtain a copy of this Notice at any time.
  • Request restrictions on how your health information is used or disclosed.
  • Request confidential communications regarding your health information.
  • Access, amend, and obtain copies of your protected health information.
  • Receive a record of disclosures made about your health information.
  • Be informed of breaches affecting your protected health information.

If you believe your privacy rights have been violated, you may file a written complaint with Audeotherapy’s Compliance Officer or the U.S. Department of Health and Human Services without fear of retaliation.

Our Responsibilities

Audeotherapy is committed to:

  • Protecting the privacy and security of your health information.
  • Using or disclosing your health information only as outlined in this Notice or authorized by you.
  • Obtaining your explicit written consent for uses not covered here, such as marketing or selling health information.
  • Notifying you of any changes to this Notice when necessary.

Acknowledgment

By receiving this Notice, you acknowledge being informed of your privacy rights. This Notice is available upon request. Audeotherapy reserves the right to amend its terms at any time, with notification provided for significant changes.

Contact Information

For further details or to file a complaint, please contact:

Audeotherapy Compliance Officer
333 N. Michigan Ave #1400, Chicago, IL 60601
info@audeotherapy.com 

Effective Date: 01/20/2025

Scroll to Top

Safety Information

Critical Details About Compounded Semaglutide

Compounded medications are legally allowed to be prescribed under federal law; however, they are not FDA-approved and do not undergo FDA evaluation for safety, efficacy, or production standards. At AudeoTherapy, compounded semaglutide is prescribed based on an individualized medical assessment.

WARNING: Potential Risk of Thyroid C-Cell Tumors
Research in animals has linked semaglutide, the active ingredient in some GLP-1 receptor agonists, to thyroid tumors, including medullary thyroid carcinoma (MTC). It is unclear if semaglutide causes similar tumors in humans. Notify your healthcare provider immediately if you notice symptoms of thyroid cancer, such as neck lumps or swelling, hoarseness, swallowing difficulties, or shortness of breath. Compounded semaglutide is not suitable for individuals with personal or family histories of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Uses of Compounded Semaglutide
Compounded semaglutide is intended for use alongside a reduced-calorie diet and increased physical activity to manage chronic weight in adults who meet the following criteria:

  • A body mass index (BMI) of 30 kg/m² or higher (classified as obesity), or
  • A BMI of 27 kg/m² or higher (overweight) with at least one weight-related condition, such as type 2 diabetes, hypertension, or abnormal cholesterol levels.

Usage Restrictions

  • Do not use compounded semaglutide in combination with other GLP-1 receptor agonists or semaglutide-containing products.
  • Its safety and effectiveness when combined with other weight management medications have not been established.
  • Patients with a history of pancreatitis or gastroparesis have not been studied for this treatment.

Avoid Use If You:

  • Have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
  • Are diagnosed with type 1 diabetes, pancreatitis, or gastroparesis.
  • Are allergic to semaglutide or any inactive ingredients.
  • Have a history of suicidal thoughts or behavior.

Precautions and Warnings:

  • Acute Pancreatitis: Stop using the medication if pancreatitis is suspected.
  • Gallbladder Issues: Monitor for symptoms of gallbladder disease, including gallstones, and seek medical advice as needed.
  • Low Blood Sugar: When combined with insulin or similar medications, there is an increased risk of hypoglycemia. Regularly monitor blood sugar and adjust doses as recommended by your provider.
  • Kidney Health: Monitor kidney function, particularly in patients with renal impairment or those experiencing severe gastrointestinal effects.
  • Mental Health Concerns: Watch for mood changes, depression, or suicidal thoughts, and discontinue use if these symptoms occur.

Pregnancy and Fertility Considerations
Semaglutide may harm an unborn child. Avoid use during pregnancy or if planning to become pregnant. Stop treatment at least two months before attempting to conceive.

Common Side Effects:
Frequently reported side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, headaches, and low blood sugar in patients with type 2 diabetes.

Potential Drug Interactions:
Compounded semaglutide slows gastric emptying, which could impact the absorption of oral medications. Consult your healthcare provider to manage potential interactions effectively.

Medication Disclaimer

Essential Information on Medications: Saxenda®, Victoza®, Wegovy®, and Ozempic® are patented products of Novo Nordisk™, while Eli Lilly and Company™ produce Mounjaro™ and Zepbound. This website is not affiliated with, endorsed by, or connected to these companies or their products in any capacity. While these FDA-approved medications may be available through other sources, we do not provide them, and they are currently experiencing supply shortages. During such shortages, pharmacies might prepare compounded versions of these drugs, provided they comply with the Federal Food, Drug, and Cosmetic Act’s requirements. Compounded medications are valuable for patients with unique medical needs that FDA-approved drugs cannot address. However, it is important to note that compounded drugs are not FDA-approved, nor do they undergo premarketing evaluations for safety, effectiveness, or quality. The FDA has not assessed these medications for their intended uses, nor has the manufacturing process for compounded drugs been reviewed by the FDA.